| Neuroendocrine Tumor Research Advances | Lifetime | 6 | US 4 | 99.91 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 3 | US 3 | 99.92 |
| Parathyroid Disorders and Treatments | Lifetime | 6 | US 6 | 99.80 |
| Peptidase Inhibition and Analysis | Lifetime | 18 | US 10 | 99.88 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 22 | US 16 | 99.90 |
| Multiple Myeloma Research and Treatments | Lifetime | 12 | US 9 | 99.91 |
| Protein Degradation and Inhibitors | Lifetime | 17 | US 12 | 99.81 |
| Dermatological and Skeletal Disorders | Lifetime | 7 | US 5 | 99.55 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 17 | US 11 | 99.75 |
| Cancer Treatment and Pharmacology | Lifetime | 51 | US 29 | 99.80 |
| Lymphoma Diagnosis and Treatment | Lifetime | 66 | US 32 | 99.75 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 50 | US 24 | 99.65 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 9 | US 5 | 99.46 |
| Pancreatitis Pathology and Treatment | Lifetime | 71 | US 30 | 99.44 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 52 | US 19 | 99.52 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 52 | US 24 | 99.23 |
| Drug Transport and Resistance Mechanisms | Lifetime | 146 | US 57 | 99.17 |
| Blood groups and transfusion | Lifetime | 104 | US 48 | 98.82 |
| Eosinophilic Disorders and Syndromes | Lifetime | 89 | US 51 | 99.12 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 161 | US 83 | 99.11 |
| Renal Diseases and Glomerulopathies | Lifetime | 230 | US 98 | 98.70 |
| Erythrocyte Function and Pathophysiology | Lifetime | 277 | US 159 | 98.05 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 179 | US 103 | 98.54 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 420 | US 227 | 98.33 |
| Medical Imaging and Pathology Studies | Lifetime | 722 | US 331 | 96.61 |
| Peripheral Neuropathies and Disorders | Lifetime | 398 | US 123 | 96.93 |
| Platelet Disorders and Treatments | Lifetime | 786 | US 309 | 96.37 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 412 | US 148 | 94.83 |
| Chemokine receptors and signaling | Lifetime | 481 | US 188 | 94.04 |
| Blood disorders and treatments | Lifetime | 795 | US 313 | 92.56 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 11 | US 4 | 99.35 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 47 | US 18 | 99.39 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 72 | US 33 | 98.98 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 57 | US 20 | 97.99 |
| Protein Degradation and Inhibitors | 2021-2025 | 61 | US 29 | 98.63 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 53 | US 33 | 98.68 |
| Parathyroid Disorders and Treatments | 2021-2025 | 47 | US 15 | 97.64 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 262 | US 130 | 97.40 |
| Peptidase Inhibition and Analysis | 2021-2025 | 224 | US 66 | 95.17 |
| Cancer Treatment and Pharmacology | 2021-2025 | 190 | US 63 | 96.29 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 25 | US 5 | 94.67 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 168 | US 41 | 92.12 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 287 | US 144 | 94.97 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 275 | US 81 | 93.58 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 446 | US 113 | 82.86 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 405 | US 79 | 85.19 |
| Dermatological and Skeletal Disorders | 2021-2025 | 143 | US 38 | 77.35 |
| Blood groups and transfusion | 2021-2025 | 787 | US 216 | 75.77 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 795 | US 267 | 71.44 |
| Protein Kinase Regulation and GTPase Signaling | 2021-2025 | 427 | US 190 | 59.37 |
| Hematological disorders and diagnostics | 2021-2025 | 936 | US 226 | 48.82 |
